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in participants compared with 16Y0in nonpatiicipants (p <0.001 between
groups). These results translate into a $660 SSVin95Per emPloYeePerYear
in medical claims costs for RAMP participants. Conclusion: Theae coat date
support the potential for work-site primary prevention programs to signifi-
cantly improve employee health which in turn reduce annual medical claims.
These programs should be considered by industry and managed haalth care
organizations in cost-effective health maintenance.
B923138 Medical Intervention in Unatsble Angina: DoesInternational Clinical Practice Match
Evidence-Baaed Guideline?
K.P.Alexander, E.D. Peterson, K.W. Mahaffey,A.C. Casas, C.B. Granger,
F.Van de Werf, P.W.Armstrong, D.B. Mark, E.J. Topol, R.M. Califf for the
GUSTO Ilb Investigators. Duke University Durham, NC, USA
Guidelines have bean asfablished for the use crfmedications in patients with
unstable angina. To determine how international clinical practice matches
these recommendations, we evaluated discharge medicstiona from 7,743
unstable angina patients enrolled in GUSTO Ilb. Using established criteria
for usa and avoidance of each medication, we examined the use of threa
medications (aspirin [ASA], bate blockers [BB], ACE inhibitors [ACEi]), and
the avoidance of a fourth (calcium blockers [CaB]). We compared medication
use at discharge in ‘All’ patients, and in ‘Ideal’ patients defined as those
eligible for each treatment without identifiable contraindications.
Medicationat US(2183) Canada(892) Europe(4468)
Discharge All Ideal All Ideal All Ideal
ASA (%) 82.2 83.9 85.2 86.4 82.5 86.1
BB(%) 52.6 58.8 65.8* 69.8* 54,0 57.3
ACEI (%) 23.4 54.6 21.1 49.2 22.3 49.1
CaB (%) 38.0 25,1+ 34.2* t8.7t 44.3 31,6t
*p <0.001 Canada vs. othara for All and Ideal use, tO/. use of CaS in PISin whom uae
was contraindicated
Corrc/usiorr.’Although Canada diaplayad a practice pattern more consis-
tent with published guidelines, all geographic regions demonstrated under-
utilization of appropriate drug therapy in unstabla angina.
m923139 10-year Trends in CHF Hospitalization Rstes,Duration and Outcome
B.M. Massie, N.B. Shah. University of California and VAMC,San Francisco,
CA, USA
CHF is a major source of morbidity and health cere costs, and therefore has
bean a target for both pharmacologic and non-pharmamlogic interventions.
To determina whether changes in hospital discharges (DC), length of stay,
and outcomes have occurred, wa examined data for CHF hospitalizations
(ICD-9 428.0) from the National Hospital Discharge Survey for 1993, the last
available year, and the preceding decade. As shown in the table, there has
been a dramatic rise DC number and rate, although this has been partially
counterbalanced by a decreasing length of stay (LOS). Although the great
majority of hospitalized patients were elderly (78% ?65; 53% >75) and
hoapital mortality rates are much higher in the elderly (7.2Y0265 vs 2.8Y0
< 66), they have deciinad from 9.7Y0to 6.IYo over 10 years. DC rates per
10,000 were higher in women then men (36.2vs32.0) and African Americans
than whites (S3.3 vs 28.6). Major regional variations were notad, with DC
rates (per 10,000) ranging from 39 in the South, 38.5 in the Northeast, 37.5
in the Midwe$t, to 18 in the West, with corresponding average LOS of 7.0,
9.5,7.1, and 6.2 days, respectively.These data indicate that CHF remains a
major health and socio-aconomic problem, but aiso suggest that changes in
management ara impacting on LOS and short-term outcome.
El923140 Over and Underuse of RevsscularizstionProcedures in Italy
F. Valagussa 1, A. Liberati 2, A.P. Maggioni 2, L. Valagussa 1, G. Filardo2,
G. Mura2. i S. Garardo /-fospita/,Monza, Italy, 2Mario Nagrihsfituta,
Mi/ano, /ta/y
Most studies on appropriateness of cardiac revascularization procedures
have been aimed at detecting “overuse” (ie when patients get a procedure
without a clear indication) whila still Iittla attention has been paid to “undar-
use” (when patients who could benefit from a procedure do not get it). A
multidisciplinary experl panel convened by the Italian Association of Hos-
pital Cardiologists (ANMCO) ratad the appropriateness of 898 “theoretical
indications” for Coronary Artery by Pass Grafting (CABG) and Percutaneous
Transluminal Angioplasfy (PTCA) using the RAND Corporation methodology.
For CABG 37% indications were considered “appropriate”, 42% “equivocal”
and 21 “inappropriate”; for PTCA corresponding figures were 23%, S5% and
22%. These criteria were compared to theacfual indications given after coro-
nary angiography to a cohorl of 1811consecutive patients seen at 16 centers
in Northern Italy in 1995 to assess the appropriateneas of clinical indications.
Fiffyeight percent patientato whom amedicsl therapy wasprescrfbsd should-
according tothepanel criteria-have received an indication for CABGor PTCA
(see below). Most of the indications for CABG were appropriate while almost
haif of the indications for PTCAfelled into the “equivocal” category, Thepapar
also presents figures on the eventual utilization of CABGIPTCA at 9 months
follow-up after angiography.
Compariaonofindicationsaftercoronaryangiographyandthecrltariaagreedbythaexpetl
panel(Pts = 1811)
Indication after Expert panel criteria
angiography Appropriate nQ(%) Equivecal nQ(OA) Inappropriata nQ(%) Totsl
Medical theraDv 57 114) 117 (28) 239 (58) 413
CABG “ 565~80j 111(14j 39 (6j 7t6
PTCA 262(39) 300(44) 121(17) 633
Total 884(49) 528 (29) 399 (22) 1811
1923-141 I Angioplasty(PTCA): Outcomes inthe Veterana
Administration (VA) snd the Privste Sector
(Washington State)
J.L. Ritchie, C. Maynard, M. Chapko, N. Every, D. Martin. Seattle Veterans
Administration /-/ospita/arrd U. of Washington, Seattle, WA, USA
Using administrative hospital discharge data, we compared 10 day mortality
between men in the VA nationally and men in the State of WA for 1993-94.
In the VA system, only 50 larger hospitals with cardiac surgety progrema
periorm PTCA. Institutional PTCA volumea were, however, generally low in
the VA (range 16-21B/yr,9/50 or 18%did ?150/yr). In WA State 1W23(560A)
canters did ?150/yr, (range 5-920, mean 266/yr). For patiants with same
admission AMI, 10 day mortality was 3.9~o in the VA (67/1727) vs. 3.5% in
WA State (97/2773), p = NS. For non AMI patients, mortality was 0.5% in the
VA (3W6599)vs 0.4% in WA State (18/4588), p = NS.
Co-morbidities of diabetes, hypertension, renal, liver and pulmonary dis-
ease, and CHF were more common in VA patienta. Co-morbidities such es
CHF (which could have been complications of the procedure), were con-
sidered only if preaent on a prior admission. With logistic regression, risk
adjusted mortality was not different in the two systems. For AMI patients, VA
axpactad mortality was 4.0% (obsarvad = 3.9~o), and WA State expected
mortality was 3.4% (obsewad 3.5%), p = NS. For non AMI patients, VA
expected mortality was 0.5?4 (obsarvsd = 0.5%), and WA State expected
mortality was 0.5% (obsewed 0.5%), p = NS.
We conclude that in a tiered national VA system, risk adjuated motility
was no differant than that of a state wide private systam.
Year Heap DCS DC Rate Hosp Daya LOS Mortality
19s3 463,000 2W1O,OOO 4,484,000 9.7d 9.7”h
19s8 624;000 2S/10,000 5,560,000 8.8 d 8.5”k
18s3 876,000 Wlo,ooo 6,567,000 7.5d 6.1”/0
